Startseite Kongressberichte & Archiv 63rd ASH Annual Meeting and Exposition In-Person/Virtual Cellular Therapies Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets

704. Cellular Immunotherapies: Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets

253

Melody Smith, Anqi Dai, Guido Ghilardi, et al.

Exposure to antibiotics, particularly piperacillin-tazobactam, imipenem-cilastatin, and meropenem, in the four weeks prior to therapy were associated with poorer survival. Consult the abstract for more information.

 

254

Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste-Burel, et al.

The administration of two doses of the BNT162b2 mRNA Covid-19 vaccine to recipients of CAR-T therapy leads to a low seroconversion rate (30%). Consult the abstract for more information.

 

255

Wei Jiang, Gaurav Sutrave, Selmir Avdic, et al.

Treatment achieved high 1-year overall survival with low rates of non-relapse mortality and relapse. For more information see the abstract.

 

256

Adam J. Lamble, Regina M. Myers, Agne Taraseviciute, et al.

For more information see the abstract.

 

257

Ying Liu, Biping Deng, Bo Hu, et al.

Sequential CAR-T-cell therapy can lead to a lasting response. Treatment is safe in pediatric Burkitt lymphoma. The authors conclude that patients with secondary CNS involvement can benefit from sequential CAR-T cell therapy.

 

258

Matthew J. Frigault, Jorg Dietrich, Kathleen M.E. Gallagher, et al. 

Tisagenlecleucel in r/r PCNSL was safe and effective in a highly refractory population. The majority showed a response according to the IPCG, including responses even more than 12 months. Tisagenlecleucel expands in the peripheral blood and in the CNS with CSF gene signatures. This indicates higher CAR-T cell infiltrates in responding patients. More data will be presented in the oral session.